10-Q: Amylyx Q3 2025: Pipeline Focus After RELYVRIO Exit

Amylyx Pharmaceuticals reports Q3 2025 results, highlighting a strategic pivot to its pipeline assets, avexitide, AMX0035, and AMX0114, following the discontinuation of RELYVRIO/ALBRIOZA.

Summary

• Net loss for the three months ended September 30, 2025, was $34.4 million, an improvement from a net loss of $72.7 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $111.7 million, significantly lower than $264.2 million for the same period in 2024.
• Product revenue was $0 for both the three and nine months ended September 30, 2025, down from $416 thousand and $88.0 million, respectively, in 2024, due to the voluntary discontinuation of RELYVRIO/ALBRIOZA.
• Research and development (R&D) expenses decreased by 7% to $19.9 million in Q3 2025 and by 15% to $69.2 million for the nine months ended September 30, 2025.
• Selling, general and administrative (SG&A) expenses decreased by 9% to $16.2 million in Q3 2025 and by 51% to $47.5 million for the nine months ended September 30, 2025, primarily due to a 70% workforce reduction in April 2024.
• Cash, cash equivalents, and marketable securities totaled $344.0 million as of September 30, 2025.
• The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2028.
• The first participant was dosed in the pivotal Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) in April 2025, with topline data expected in Q3 2026.
• Positive long-term data through Week 48 from the Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome showed sustained improvement or stabilization in pancreatic beta cell function, glycemic control, and visual acuity.
• Cohort 1 (n=12) of the Phase 1 LUMINA clinical trial for AMX0114 in amyotrophic lateral sclerosis (ALS) was fully enrolled in September 2025, with early cohort data expected in December 2025 and biomarker data in H1 2026.
• The ORION program of AMX0035 in progressive supranuclear palsy (PSP) was discontinued in August 2025 due to lack of efficacy.
• The company raised approximately $65.5 million in January 2025 and $190.7 million in September 2025 through public offerings of common stock.
• Multiple legal proceedings, including class action and derivative lawsuits, are ongoing, alleging false and misleading statements related to RELYVRIO's commercial results and prospects.

Sentiment

Score: 4

Explanation: While the company successfully raised significant capital and is advancing its pipeline, the complete cessation of product revenue and the discontinuation of a clinical program (PSP) are major setbacks. The positive clinical updates for Wolfram syndrome and PBH are promising but still early or mid-stage, and the company remains highly speculative with substantial future funding needs and ongoing losses. The legal proceedings add further uncertainty.

Positives

• Successfully raised approximately $256.2 million (net) through two public offerings in 2025, significantly strengthening the balance sheet and extending the cash runway into 2028.
• Initiated the pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH, a key step for the lead investigational asset, with topline data anticipated in Q3 2026.
• Reported positive long-term data from the Phase 2 HELIOS trial for AMX0035 in Wolfram syndrome, demonstrating sustained improvements or stabilization in pancreatic function, glycemic control, and visual acuity.
• Fully enrolled cohort 1 of the Phase 1 LUMINA trial for AMX0114 in ALS, marking progress in a new neurodegenerative program.
• Achieved significant reductions in operating expenses, particularly SG&A (51% decrease for 9M 2025), due to the 2024 restructuring plan, contributing to a lower net loss compared to the prior year.
• Avexitide holds Breakthrough Therapy Designation for PBH and congenital hyperinsulinism (HI), Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for hyperinsulinemic hypoglycemia, which could expedite development and provide market exclusivity.
• AMX0114 has been granted Fast Track designation for the treatment of ALS, potentially accelerating its development and review process.

Negatives

• Experienced a complete cessation of product revenue in 2025 due to the voluntary discontinuation of RELYVRIO/ALBRIOZA from the market, eliminating the company's only commercial product.
• Discontinued the AMX0035 ORION program in progressive supranuclear palsy (PSP) in August 2025, following a Phase 2b trial that did not show differences compared to placebo on primary or secondary outcomes.
• Continues to incur significant net losses, with an accumulated deficit of $718.4 million as of September 30, 2025, indicating ongoing unprofitability.
• Facing multiple legal proceedings, including a class action lawsuit and two derivative complaints, alleging violations related to RELYVRIO's commercial prospects, which could lead to substantial costs and liabilities.
• Interest income decreased by 41% in Q3 2025 and 48% for the nine months ended September 30, 2025, compared to the prior year, potentially reflecting lower returns on investments or changes in cash management.

Risks

• Inability to obtain regulatory approvals for avexitide, AMX0035, AMX0114, or any other current or future product candidates, or experiencing significant delays in doing so.
• Heavy dependence on third parties for conducting clinical trials and manufacturing, with risks of unsatisfactory performance, delays, or non-compliance with cGMP.
• The markets for avexitide (PBH, congenital HI) and AMX0035 (Wolfram syndrome) may be smaller than expected, potentially limiting commercial opportunity.
• Challenges in expanding sales, marketing, manufacturing, and distribution capabilities or securing third-party agreements for commercialization.
• Failure of any approved product to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Potential for undesirable side effects or other properties of product candidates that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Exposure to product liability and professional indemnity risks inherent in pharmaceutical product development and commercialization.
• Inability to obtain adequate coverage and reimbursement from third-party payors for approved products.
• Ongoing healthcare legislative and regulatory reform measures that could adversely affect drug pricing, reimbursement, and market access.
• Cyber-attacks, data breaches, or failures in IT systems of the company or its partners, leading to information theft, business disruption, and reputational damage.
• Limitations on the ability to use net operating losses (NOLs) and research and development credits to offset future taxable income due to ownership changes under Sections 382 and 383 of the IRC.
• Volatility in stock price due to clinical trial results, regulatory decisions, market expectations, and broader economic conditions.
• Potential for dilution from future sales and issuances of common stock or rights to purchase common stock.
• Risk of delisting from Nasdaq if continued listing requirements are not met.
• Uncertainty in intellectual property protection, including challenges to patents, inability to enforce rights globally, and reliance on trade secrets.
• Economic uncertainty and capital markets disruption due to geopolitical instability, military conflicts (Ukraine, Israel-Hamas), inflation, and interest rates, impacting supply chains and funding.
• Inadequate funding for regulatory agencies (FDA, SEC, NIH) or government shutdowns hindering their ability to perform functions critical to the business.
• Dependence on executive officers and key personnel, with the risk of loss of their services.
• Risks associated with strategic transactions, acquisitions, or business combinations, including integration difficulties and failure to realize anticipated benefits.
• Employees, independent contractors, consultants, collaborators, and CROs engaging in misconduct or non-compliance with regulatory standards.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future but believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2028. Research and development expenses are anticipated to increase in the near term and future due to planned clinical development activities, while selling, general and administrative expenses are also expected to rise as the clinical pipeline advances. A decision on a potential development candidate for the GLP-1 receptor antagonist collaboration with Gubra A/S is expected in the next few months, followed by IND-enabling studies. Recruitment for the Phase 3 LUCIDITY trial for avexitide in PBH is expected to complete in Q1 2026, with topline data in Q3 2026 and commercial launch in 2027, if approved. A pivotal Phase 3 trial for AMX0035 in Wolfram syndrome is planned for H2 2026, pending FDA alignment. Early cohort data from the Phase 1 LUMINA trial for AMX0114 in ALS is expected in December 2025, with biomarker data in H1 2026. The company does not expect to incur material income taxes for the foreseeable future.

Management Comments

• "We are a clinical-stage pharmaceutical company with a mission to develop novel therapies for communities with high unmet medical needs."
• "We are advancing a pipeline in which we have matched investigational therapies with diseases where we believe they can make the greatest impact, based on well-defined mechanistic rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality."
• "We expect to make a decision on a potential development candidate in the next few months, and pending a candidate nomination, expect to initiate Investigational New Drug (IND)-enabling studies [for the GLP-1 receptor antagonist collaboration]."
• "We expect to complete recruitment in the first quarter of 2026, with topline data expected in the third quarter of 2026 [for LUCIDITY trial]."
• "We continue to expect to commercially launch avexitide in 2027, if approved."
• "We are advancing the clinical development of AMX0035 in Wolfram syndrome and, pending alignment with the FDA, plan to initiate a focused, pivotal Phase 3 trial in the second half of 2026."
• "Based on biomarker collection and analysis timelines, we anticipate biomarker data will be available in the coming months and expect to present these at a medical meeting in the first half of 2026 [for LUMINA trial]."
• "We believe our existing cash, cash equivalents and marketable securities as of September 30, 2025 will be sufficient to fund our operations into 2028."

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industries, particularly in neurodegenerative diseases, a field with limited historical success in product development. The strategic shift to endocrine and metabolic conditions with avexitide represents an expansion into an area where the company has limited prior experience. The discontinuation of RELYVRIO/ALBRIOZA highlights the high failure rate in drug development, even for approved products, and the significant upfront capital expenditures required. The increasing demand for GLP-1 and other peptide-based therapeutics (relevant to avexitide and the Gubra collaboration) indicates a growing market but also increased competition for manufacturing and supply. The regulatory environment is complex and unpredictable, with potential impacts from U.S. Supreme Court decisions, changes in FDA staffing/policies, and ongoing healthcare reform measures that could affect drug pricing, reimbursement, and market access. The company's focus on rare diseases presents challenges in patient enrollment and market size estimation, but also opportunities for orphan drug designations and expedited review pathways.

Comparison to Industry Standards

• The discontinuation of RELYVRIO/ALBRIOZA due to a failed Phase 3 trial (PHOENIX) after initial approval (based on CENTAUR) is a stark reminder of the challenges in drug development, particularly in ALS, where many companies have faced setbacks. This contrasts with successful ALS drug launches like Biogen's Qalsody (for a specific genetic form) or Mitsubishi Tanabe Pharma's Radicava, highlighting the difficulty of bringing effective treatments to market for this complex disease.
• The positive Phase 2 data for AMX0035 in Wolfram syndrome is promising for a rare disease with no approved therapies, potentially positioning it favorably against the high unmet medical need, similar to other orphan drug developments for rare genetic disorders.
• The Phase 3 LUCIDITY trial for avexitide in PBH targets a condition with no FDA-approved therapies, offering a significant market opportunity if successful, comparable to other first-in-class therapies for rare endocrine conditions.
• The company's substantial capital raises are typical for clinical-stage biopharma companies needing to fund extensive research and development, aligning with industry norms for companies with a pipeline of investigational assets.

Management Changes

Corporate Governance

Legal Proceedings

• **Shih v. Amylyx Pharmaceuticals, Inc., et al.** (Class Action Lawsuit): Filed February 9, 2024, alleging violations of Section 10(b) of the Exchange Act and Rule 10b-5 related to materially false and misleading statements about RELYVRIO's commercial results and prospects. The defendants' motion to dismiss was denied on September 30, 2025, and the company filed an answer on October 30, 2025. Seeks unspecified damages, interest, costs, and attorneys' fees.
• **Jones v. Cohen, et al.** (Derivative Complaint): Filed October 2, 2024, mirroring allegations of the Shih Complaint and including claims for alleged violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, insider trading, and unjust enrichment against current and former directors/officers. The action was stayed on October 31, 2024, pending resolution of the Shih Complaint. Seeks unspecified damages to the company, interest, restitution, corporate governance reforms, and attorneys' fees/costs.
• **Hassine v. Cohen, et al.** (Second Derivative Complaint): Filed July 2, 2025, with substantive allegations mirroring the Shih Complaint and additional claims for alleged violations of Sections 14(a), 10(b), and 21D of the Exchange Act, breach of fiduciary duty, and other common law claims. Consolidated with the Jones Derivative Complaint and stayed on July 22, 2025. Seeks unspecified damages to the company, interest, costs, attorneys' fees, restitution, and corporate governance reforms.

Stakeholder Impact

• **Shareholders**: Experienced dilution from recent public offerings. Face potential for stock price volatility due to clinical trial outcomes, regulatory decisions, and ongoing legal proceedings. Potential for long-term value if pipeline assets succeed.
• **Employees**: Underwent a significant workforce reduction of approximately 70% in April 2024 due to a restructuring plan. Continued stock-based compensation is a component of employee benefits.
• **Customers/Patients**: Discontinuation of RELYVRIO/ALBRIOZA means patients no longer have access to that product. Potential for new therapies (avexitide, AMX0035, AMX0114) for unmet medical needs in PBH, Wolfram syndrome, and ALS.
• **Suppliers/Creditors**: Engaged in ongoing negotiations with third-party manufacturers following the RELYVRIO/ALBRIOZA discontinuation, which could impact relationships. The company remains dependent on single-source suppliers for active pharmaceutical ingredients (APIs).
• **Regulatory Bodies**: Subject to ongoing scrutiny and compliance requirements for clinical trials, manufacturing processes, and marketing activities for its investigational therapies.

Next Steps

• Make a decision on a potential development candidate for the GLP-1 receptor antagonist collaboration with Gubra A/S in the next few months.
• Initiate IND-enabling studies for the GLP-1 receptor antagonist candidate, pending nomination.
• Complete recruitment for the Phase 3 LUCIDITY clinical trial for avexitide in PBH in Q1 2026.
• Present early cohort data from the Phase 1 LUMINA trial for AMX0114 in ALS at the 36th International Symposium on ALS/MND (December 5-7, 2025).
• Present biomarker data from the Phase 1 LUMINA trial for AMX0114 in ALS at a medical meeting in H1 2026.
• Expect topline data from the Phase 3 LUCIDITY trial for avexitide in PBH in Q3 2026.
• Plan to initiate a focused, pivotal Phase 3 trial for AMX0035 in Wolfram syndrome in H2 2026, pending alignment with the FDA.
• Commercially launch avexitide in 2027, if approved.
• Continue to evaluate plans to explore the use of AMX0035 in patients with AD and other product candidates in ALS and additional neurodegenerative diseases.
• Meet and confer with parties to either extend the stay or propose a schedule for the consolidated derivative action (legal proceedings).

Key Dates

Recommendation

The company is in a high-risk, high-reward transition phase. The discontinuation of its only commercial product (RELYVRIO/ALBRIOZA) is a major negative, but the subsequent capital raises have significantly strengthened its balance sheet, providing a runway into 2028. Positive Phase 2 data for AMX0035 in Wolfram syndrome and the initiation of a pivotal Phase 3 for avexitide in PBH offer future potential. However, these are still investigational therapies with inherent clinical and regulatory risks. The ongoing legal proceedings add a layer of uncertainty. A 'Hold' recommendation reflects the speculative nature of the pipeline, the financial stability provided by recent capital raises, and the significant risks that still need to be navigated before a clear path to profitability can be established. Investors should monitor clinical trial results and regulatory progress closely.

Keywords

Amylyx Pharmaceuticals, Biotechnology, Neurodegenerative diseases, Endocrine conditions, Avexitide, AMX0035, AMX0114, Post-bariatric hypoglycemia (PBH), Wolfram syndrome, Amyotrophic lateral sclerosis (ALS), Clinical trials, Phase 3 LUCIDITY, Phase 2 HELIOS, Phase 1 LUMINA, Orphan drug, Breakthrough Therapy Designation, Fast Track Designation, SEC filing, 10-Q, Financial results, Drug development, Pharmaceuticals, Biopharma